Brielle Benyon

Ado-trastuzumab emtansine led to improved overall survival and invasive disease–free survival over trastuzumab in patients with HER2-positive early breast cancer who had residual invasive disease after neoadjuvant therapy.

Targeted therapy, as determined by genomic profiling, outperformed standard of care in patients with pretreated metastatic cancers.

Linvoseltamab may have similar — if not better — outcomes compared with teclistamab for patients with triple-class exposed relapsed or refractory multiple myeloma.

Treatment with talquetamab demonstrated promising safety and efficacy findings when used in relapsed/refractory multiple myeloma, including patients with comorbidities and poor functional status.

Frontline amivantamab plus lazertinib reduced the risk of disease progression or death by 30% versus osimertinib in patients with high-risk EGFR-mutant non–small cell lung cancer.

A new brentuximab vedotin-containing regimen for classical Hodgkin lymphoma has been shown to be more tolerable and effective than the current standard.

A study offers promising news for young women with early-stage breast cancer who want to have children after treatment, showing that 73% of breast cancer survivors who attempted pregnancy were successful.

While germline and somatic testing is standard of care in the metastatic castration-resistant prostate cancer setting, it is still underutilized in the real world, leading to negative impacts on therapeutic offerings.

Clinical characteristics were associated with long-term remission to regorafenib in patients with metastatic colorectal cancer.

Treatment with the novel agent NX-2127 was safe and efficacious in patients with B-cell malignancies, according to recent phase I data.

After more than 8 years of follow-up, T-DM1 continued to improve invasive disease-free survival and overall survival in patients with HER2-positive early breast cancer that had residual invasive disease.

Adjuvant ribociclib plus standard non-steroidal aromatase inhibitors improved invasive disease-free survival in HR-positive, HER2-negative early breast cancer, compared with nonsteroidal aromatase inhibitors alone.

Older patients with stage 4 cancer often prioritize quality of life over survival time, according to recent research findings presented at the 2023 American Society of Clinical Oncology Quality Care Symposium.

Belzutifan led to improved progression-free survival and objective response rate compared to everolimus for patients with advanced clear cell renal cell carcinoma, according to study findings.

Older with chronic lymphocytic leukemia patients been underrepresented in clinical trials. The phase 2 CLL-FRAIL trial focuses on this population.

Correlative work is ongoing following positive results from the phase 1 study of cabozantinib with nivolumab and ipilimumab.

Treating patients with metastatic castration-resistant prostate cancer with 177Lu-PSMA-617 within 6 months of completing radium showed to be clinically feasible and well tolerated.

Patients with chronic lymphocytic leukemia on frontline acalabrutinib were more likely to switch to another therapy or intensify their treatment earlier on, compared to those on ibrutinib, according to real-world study data.

MAGNOLIA study results demonstrated that zanubrutinib maintained response in patients with relapsed/refractory marginal zone lymphoma.

After extended follow-up, continued benefit was seen with the combination of lenvatinib and pembrolizumab in patients with advanced endometrial cancer who previously received platinum chemotherapy, updated efficacy and safety findings from the phase 3 Study 309/KEYNOTE-775 trial showed.

Adding tiragolumab to atezolizumab plus carboplatin and etoposide did not meet its mark of improving survival in patients with extensive-stage small-cell lung cancer.

Decreased risk of disease progression or death on second-line therapy with the combination of lenvatinib and pembrolizumab vs sunitinib in the CLEAR clinical trial.

Among patients with newly diagnosed, transplant-eligible myeloma treated in a phase 2 study, induction and consolidation with daratumumab plus the RVd regimen outperformed RVd alone in terms of minimal residual disease and progression-free survival.

An analysis presented during the 2022 ASCO Annual Meeting reveals that pacritinib's safety profile is comparable with beast available therapy, including ruxolitinib.

Findings from the use of mutimodal interventional therapy of lenvatinib and transarterial therapy may lay the groundwork for future research regarding the combination for the treatment of patients with hepatocellular carcinoma.

A recent study found no difference in invasive disease–free survival between patients with HER2-negative breast cancer who took a full-strength aspirin daily and those who did not.

The treatment and preventive agent landscape for graft-versus-host disease is growing for patients with hematologic malignancies who receive a stem cell transplant.

Tivozanib as first-line treatment showed noninferiority compared with other tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma in a real-world setting. This is an attractive option for patients due to tivozanib’s tolerable safety profile.

The combination of transarterial chemoembolization, lenvatinib, and PD-1 checkpoint blockade demonstrated tolerable safety and efficacy in patients with unresectable advanced hepatocellular carcinoma.

Having knowledge that their multiple myeloma was incurable was associated with poor quality of life outcomes in patients.